{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T02:07:23Z","timestamp":1771553243301,"version":"3.50.1"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T00:00:00Z","timestamp":1642377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>The vaccine is still the best clinical measure for effective prevention and control of coronavirus disease 2019 (COVID-19). The vaccine-associated ocular adverse reactions should be noted in detail among the medical community. We reported twelve eyes of 9 patients presented at the Department of Ophthalmology, Qilu Hospital of Shandong University from March to August 2021 with ocular complaints following COVID-19 vaccination. The main inclusion criterion was the development of ocular symptoms within 14 days after receiving a dose of an inactivated COVID-19 vaccine. The mean (SD) age was 44.7 \u00b1 16.5 years (range, 19\u201378 years), among which seven (77.8%) cases were women. The mean time of ocular adverse events was 7.1 days (range, 1\u201314 days) after receiving the inactivated COVID-19 vaccine. One patient was diagnosed with choroiditis, 1 with uveitis, 4 with keratitis, 1 with scleritis, 1 with acute retinal necrosis, and 1 with iridocyclitis. Although the causal relationship between vaccines and ocular adverse events cannot be established from this case series report, physicians should pay attention to the ocular adverse reactions following the COVID-19 vaccine administration.<\/jats:p>","DOI":"10.3389\/fmed.2021.823346","type":"journal-article","created":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T07:03:22Z","timestamp":1642403002000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["Case Report: Associated Ocular Adverse Reactions With Inactivated COVID-19 Vaccine in China"],"prefix":"10.3389","volume":"8","author":[{"given":"Kunpeng","family":"Pang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijie","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,17]]},"reference":[{"key":"B1","unstructured":"2021"},{"key":"B2","doi-asserted-by":"publisher","first-page":"114184","DOI":"10.1016\/j.bcp.2020.114184","article-title":"COVID-19: An overview of the current pharmacological interventions, vaccines, and clinical trials","volume":"180","author":"Chakraborty","year":"2020","journal-title":"Biochem Pharmacol."},{"key":"B3","doi-asserted-by":"crossref","DOI":"10.1016\/j.survophthal.2021.04.001","article-title":"Ocular adverse events following vaccination: overview and update","volume-title":"Surv Ophthalmol","author":"Cheng","year":"2021"},{"key":"B4","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1038\/s41563-020-0746-0","article-title":"Next-generation vaccine platforms for COVID-19","volume":"19","author":"van Riel","year":"2020","journal-title":"Nat Mater."},{"key":"B5","article-title":"Innovations and development of Covid-19 vaccines: a patent review","volume-title":"J Infect Public Health","author":"Alshrari","year":"2021"},{"key":"B6","unstructured":"2021"},{"key":"B7","first-page":"48","article-title":"Vaccine-Associated Uveitis","volume":"113","author":"Benage","year":"2016","journal-title":"Mo Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ijid.2021.07.035","article-title":"Anterior uveitis onset after bnt162b2 vaccination: is this just a coincidence?","volume":"110","author":"Renisi","year":"2021","journal-title":"Int J Infect Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1080\/09273948.2019.1626188","article-title":"Vaccine-associated uveitis","volume":"27","author":"Cunningham","year":"2019","journal-title":"Ocul Immunol Inflamm."},{"key":"B10","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/1044-579X(95)90007-1","article-title":"Selection of potent immunological adjuvants for vaccine construction","volume":"6","author":"McElrath","year":"1995","journal-title":"Semin Cancer Biol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.immuni.2010.10.002","article-title":"Vaccine adjuvants: putting innate immunity to work","volume":"33","author":"Coffman","year":"2010","journal-title":"Immunity."},{"key":"B12","doi-asserted-by":"publisher","first-page":"64","DOI":"10.31138\/mjr.28.2.64","article-title":"The ASIA syndrome: basic concepts","volume":"28","author":"Watad","year":"2017","journal-title":"Mediterr J Rheumatol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1177\/0961203309345724","article-title":"Adjuvants and autoimmunity","volume":"18","author":"Israeli","year":"2009","journal-title":"Lupus."},{"key":"B14","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1177\/0961203316686406","article-title":"Autoimmune\/inflammatory syndrome induced by adjuvants (Shoenfeld's syndrome)\u2014an update","volume":"26","author":"Watad","year":"2017","journal-title":"Lupus."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09273948.2021.1986548","article-title":"Herpes simplex virus keratitis reactivation after SARS-CoV-2 BNT162b2 mRNA vaccination: a report of two cases","volume":"12","author":"Alkhalifah","year":"2021","journal-title":"Ocul Immunol Inflamm"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bcr-2021-245792","article-title":"Reactivation of herpes simplex keratitis following vaccination for COVID-19","volume":"14","author":"Richardson-May","year":"2021","journal-title":"BMJ Case Rep."},{"key":"B17","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1358\/dot.2017.53.7.2667582","article-title":"Keratitis in association with herpes zoster and varicella vaccines","volume":"53","author":"Grillo","year":"2017","journal-title":"Drugs of Today."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1001\/jamaophthalmol.2021.3477","article-title":"Association of ocular adverse events with inactivated COVID-19 vaccination in patients in Abu Dhabi","volume":"139","author":"Pichi","year":"2021","journal-title":"JAMA Ophthalmol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e1056","DOI":"10.1111\/aos.14484","article-title":"Episcleritis as an ocular manifestation in a patient with COVID-19","volume":"98","author":"M\u00e9ndez Mangana","year":"2020","journal-title":"Acta Ophthalmol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1097\/ICO.0000000000002795","article-title":"Anterior scleritis manifesting after coronavirus disease 2019: a report of two cases","volume":"40","author":"Feizi","year":"2021","journal-title":"Cornea."},{"key":"B21","doi-asserted-by":"publisher","first-page":"11206721211046484","DOI":"10.1177\/11206721211046485","article-title":"Reactivation of varicella zoster infection presenting as acute retinal necrosis post COVID 19 vaccination in an Asian Indian male","volume":"18","author":"Mishra","year":"2021","journal-title":"Eur J Ophthalmol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2021\/7336488","article-title":"Reactivation of acute retinal necrosis following SARS-CoV-2 infection","volume":"2021","author":"Gonzalez","year":"2021","journal-title":"Case Rep Ophthalmol Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1080\/09273948.2021.1938135","article-title":"Acute retinal necrosis as a presenting ophthalmic manifestation in COVID 19 recovered patients","volume":"29","author":"Soni","year":"2021","journal-title":"Ocul Immunol Inflamm."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1120672120974941","DOI":"10.1177\/1120672120974941","article-title":"Atypical bilateral acute retinal necrosis in a coronavirus disease 2019 positive immunosuppressed patient","volume":"22","author":"Gupta","year":"2020","journal-title":"Eur J Ophthalmol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.823346\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T07:03:27Z","timestamp":1642403007000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.823346\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,17]]},"references-count":24,"alternative-id":["10.3389\/fmed.2021.823346"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.823346","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,17]]},"article-number":"823346"}}